What are the actual regulations for a primary care physician to prescribe Adderall (mixed amphetamine salts) after a psychiatrist has documented a diagnosis of ADHD?

Primary Care Prescribing of Adderall After Psychiatric Diagnosis

Any physician with a valid DEA license for Schedule II controlled substances can legally prescribe Adderall (mixed amphetamine salts) for ADHD once a diagnosis has been established, regardless of whether that diagnosis was made by a psychiatrist or the primary care physician themselves. There are no federal or state regulations requiring ongoing psychiatric involvement for stimulant prescribing in ADHD 1.

Legal and Regulatory Framework

The key regulatory requirement is that Adderall is a Schedule II controlled substance requiring:

• A valid DEA registration
• Secure prescription practices (written or electronic prescriptions only; no phone-in refills)
• Proper documentation of medical necessity 1

There is no legal requirement for a psychiatrist to initiate or continue prescribing stimulants. Primary care physicians are fully authorized to diagnose and treat ADHD independently 2, 3.

Clinical Practice Standards

Diagnosis Requirements

Before prescribing, ensure the diagnosis meets DSM-5 criteria with:

• Documentation of symptoms in more than one major setting (home, work/school, social)
• Information from multiple sources (patient, family members, teachers/employers when applicable)
• Ruling out alternative causes 2

If a psychiatrist has already documented this diagnosis, you can proceed with prescribing without repeating the full diagnostic workup, though reviewing the psychiatric documentation is prudent.

Prescribing Protocol

Starting doses for adults:

• Begin with 5 mg once or twice daily of immediate-release mixed amphetamine salts
• Titrate upward in 5-10 mg increments weekly based on symptom response and tolerability
• Maximum typical daily doses: 40 mg total (though some patients may require up to 0.9 mg/kg or 40 mg with clear documentation of need) 4

Monitoring requirements:

• Baseline: Blood pressure, pulse, height, weight, cardiovascular history
• Weekly during titration: Symptom ratings and side effects (can be done by phone)
• After stabilization: Follow-up every 3 months minimum 4
• Document that higher doses (if needed) are necessary because lower doses were inadequate and that side effects are acceptable 4

Safety Considerations

Cardiovascular screening is essential:

• Obtain cardiovascular history and family history of sudden cardiac death
• Baseline ECG if any cardiac concerns
• Monitor blood pressure and pulse at each visit 4

Red flags requiring caution or specialist consultation:

• Active substance use disorder (particularly stimulant misuse)
• Significant cardiovascular disease
• Uncontrolled hypertension
• History of psychosis or bipolar disorder
• Request for immediate-release formulations in young adults without prior ADHD treatment history (higher diversion risk) 5

Practical Algorithm

For patients with established psychiatric diagnosis:

1. Review psychiatric documentation to confirm DSM-5 criteria were met with multi-setting impairment
2. Obtain baseline vitals (BP, pulse) and cardiovascular screening
3. Start low: 5 mg once or twice daily
4. Titrate weekly by 5-10 mg increments based on response
5. Monitor weekly during titration (phone contact acceptable) for efficacy and side effects
6. Stabilize and maintain: Once optimal dose found, see every 3 months with monthly prescription refills
7. Document clearly: Medical necessity, dose rationale, monitoring of side effects, and absence of misuse

Primary care physicians can safely manage ADHD with stimulants 3. Research demonstrates high agreement between PCPs and patients on pharmacological treatment, low rates of misuse when properly monitored, and safe outcomes when appropriate protocols are followed 3.

Common Pitfalls to Avoid

• Don't assume you need ongoing psychiatric involvement - you are legally and clinically authorized to prescribe independently once diagnosis is established
• Don't skip cardiovascular screening - this is where serious adverse events occur
• Don't prescribe immediate-release formulations to treatment-naive young adults requesting them - this population has higher diversion risk; prefer extended-release formulations 5
• Don't fail to document - with Schedule II substances, clear documentation of medical necessity and monitoring is essential
• Don't exceed typical maximum doses without clear justification - document why lower doses were inadequate 4

The evidence strongly supports that primary care management of ADHD with stimulants is both safe and effective when proper diagnostic criteria are met and appropriate monitoring is maintained 2, 3.